DavidBrianKarpfMD

Diabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine

Adj. Clinical Professor of Endocrinology, Gerontology & Metabolism Stanford University School of Medicine Attending, Osteoporosis & Metabolic Bone Disease Clinic Stanford University Hospital & Clinics Co-Chair, MSAB American Bone Health, Fellow, ASBMR Senior Endocrine Advisor Spruce Biosciences Senior Endocrine Advisor Calcilytix

Join to view full profile

Dr. Karpf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karpf's full profile

Already have an account?

Office
120 Harmony Ct
Santa Cruz, CA 95062
Phone+1 650-721-1300

Fax+1 650-646-9199

Education & Training

UCLA-VA Greater Los AngelesFellowship, Endocrinology, Diabetes, and Metabolism, 1984 - 1985
Cedars-Sinai Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1983 - 1985
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1980 - 1983
University of California San Diego School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1981 - 2024
NJ State Medical License 1996 - 1997
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Fellow ASBMR, 2020
NIH FIRST Award NIH, 1991
Merit Review Award, VAMC-SF VA, 1989
Research Associate Award, VAMC-SF VA, 1989
Merck, Sharp & Dohme Young Investigator Award ASBMR, 1988
Associate Investigator Award, VAMC-SF VA, 1986
Magna cum Laude, UC Berkeley UC Berkeley, 1976
Presidential Fellowship, University of California, Berkeley UC Berkeley, 1975
UCLA High School Honors Program UCLA, 1971-1972
National Merit Scholar National Merit Scholarship Corp., 1971
Join now to see all

Clinical Trials

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Start of enrollment: 2016 Dec 13
Completed
Phase 3
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency Start of enrollment: 2017 Nov 13
Completed
Phase 3
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial Start of enrollment: 2017 Dec 19
Completed
Phase 3
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism Start of enrollment: 2019 Aug 27
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1641 citations
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Uri A. Liberman, Stuart R. Weiss, Johann Broll, Helmut W. Minne, Hui Quan
The New England Journal of Medicine. 1995-11-30
186 citations
Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial
Susan L. Greenspan, Robert A. Parker, Lauren Ferguson, Harold N. Rosen, Lauri Maitland-Ramsey
Journal of Bone and Mineral Research. 1998-09-01
532 citations
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
Steven R. Cummings, David B. Karpf, Fran Harris, Harry K. Genant, Kristine E. Ensrud
The American Journal of Medicine. 2002-03-01

Press Mentions

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical UpdatesMay 3rd, 2023
CEO Update: Interview with Lumos Pharma's Chief Medical Officer, David B. Karpf, M.D.July 26th, 2022
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
Join now to see all

Professional Memberships

Endocrine Society - ENDO
Member